Retatrutide is not FDA approved as of April 2026. Phase 3 TRIUMPH trials are ongoing, with an estimated NDA submission in 2026–2027 and potential FDA approval in 2027–2028. Here is the complete regulatory timeline, what Phase 3 needs to show, and what approval would mean for the obesity drug landscape.
Retatrutide is not FDA approved for any indication. Phase 3 TRIUMPH trials are currently enrolling and conducting. Research-grade retatrutide is available from verified suppliers like Purgo Labs for research purposes only.
Safety, tolerability, and PK/PD in healthy volunteers. Dose-ranging established.
NCT04881760: ~24% weight loss at 48 weeks (n=338). Highest Phase 2 obesity result ever recorded.
Multiple trials: obesity, T2D, cardiovascular outcomes. Estimated completion: late 2026.
Eli Lilly submits New Drug Application to FDA following Phase 3 completion. Potential Priority Review.
Standard review: 10–12 months. Priority Review: 6 months. Breakthrough Therapy could accelerate.
Estimated approval for obesity indication. T2D and CV indications may follow 12–18 months later.
The Phase 3 TRIUMPH (TRIple hormone receptor agonist for Unmet Medical need in Patients with Obesity and Metabolic conditions with High cardiovascular risk) program is Eli Lilly's pivotal trial program for retatrutide. Phase 3 trials are the final stage of clinical development before NDA submission to the FDA — they must demonstrate both efficacy and long-term safety in large, diverse populations.
For FDA approval of the obesity indication, Phase 3 trials must show: at least 5% greater weight loss than placebo, and at least 35% of participants achieving ≥5% weight loss. Based on Phase 2 data (~24% weight loss), retatrutide is expected to comfortably meet both thresholds. The more critical question for Phase 3 is long-term safety — particularly cardiovascular outcomes, thyroid effects, and pancreatitis risk.
Chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity. Primary endpoint: % weight loss vs placebo at 72 weeks.
Glycemic control and weight loss in T2D patients. Primary endpoint: HbA1c reduction and % weight loss.
MACE reduction in high-CV-risk patients. Modeled on SUSTAIN-6 (semaglutide) and SURPASS-CVOT (tirzepatide).
If Phase 3 data confirms Phase 2 efficacy, retatrutide would become the most effective FDA-approved anti-obesity medication by a significant margin. Semaglutide (Wegovy) achieves ~15% weight loss and tirzepatide (Zepbound) achieves ~20–22% — retatrutide's ~24% would represent a meaningful step-change in the drug administration options available to physicians treating obesity.
The cardiovascular outcomes data from Phase 3 will be particularly important. Semaglutide's FLOW trial demonstrated kidney protection benefits that expanded its clinical use significantly. If retatrutide shows similar or superior cardiovascular benefits, it could become the preferred first-line option for patients with obesity and high cardiovascular risk — a very large patient population.
| Drug | Approval Status | Weight Loss | Mechanism |
|---|---|---|---|
| Semaglutide (Wegovy) | FDA Approved (2021) | ~15% | GLP-1 agonist |
| Tirzepatide (Zepbound) | FDA Approved (2023) | ~20–22% | GLP-1 + GIP dual agonist |
| Retatrutide | Phase 3 — est. 2027–2028 | ~24% (Phase 2) | GLP-1 + GIP + Glucagon triple agonist |
No. As of April 2026, retatrutide is not FDA approved for any indication. It is currently in Phase 3 clinical trials for obesity and type 2 diabetes. Phase 2 trials completed in 2023 showed ~24% average weight loss at 48 weeks — the highest ever recorded in a Phase 2 obesity trial. Phase 3 trials are expected to complete in 2026–2027, with an NDA submission and potential FDA approval estimated for 2027–2028.
Based on current Phase 3 trial timelines, retatrutide FDA approval is estimated for 2027–2028. Phase 3 trials (TRIUMPH program) began enrolling in late 2023 and are expected to complete by late 2026. Following trial completion, Eli Lilly would need to submit a New Drug Application (NDA) and receive FDA review, which typically takes 6–12 months under Priority Review. If Phase 3 data is strong, retatrutide could receive Breakthrough Therapy designation, potentially accelerating the timeline.
Retatrutide is currently in Phase 3 clinical trials. Phase 2 trials (NCT04881760) completed in 2023, showing ~24% mean weight loss at 48 weeks. The Phase 3 TRIUMPH program includes multiple trials for obesity, type 2 diabetes, and cardiovascular outcomes. Phase 3 trials are the final stage before NDA submission to the FDA.
Retatrutide has not yet received Breakthrough Therapy designation as of April 2026. However, given its Phase 2 efficacy data (the highest weight loss ever recorded in a Phase 2 trial), it is a strong candidate. Breakthrough Therapy designation would accelerate FDA review from the standard 10–12 months to approximately 6 months, potentially bringing the approval date forward to 2027.
Retatrutide is being developed for chronic weight management (obesity) and type 2 diabetes as primary indications, consistent with the GLP-class precedent set by semaglutide and tirzepatide. Additional indications under investigation include cardiovascular outcomes (heart disease risk reduction), non-alcoholic fatty liver disease (NAFLD/NASH), and potentially chronic kidney disease. The obesity indication is expected to be the first approved.
Research-grade retatrutide is available from verified suppliers like Purgo Labs for research purposes only. It is not available as a prescription medication in the US prior to FDA approval. Purgo Labs provides pharmaceutical-grade retatrutide with third-party COAs confirming ≥99% purity. All compounds are sold strictly for research purposes.
Retatrutide's Phase 2 data (~24% weight loss) exceeds both FDA-approved semaglutide (Wegovy, ~15%) and tirzepatide (Zepbound, ~20–22%). If Phase 3 data confirms Phase 2 efficacy, retatrutide would be the most effective approved anti-obesity medication by a significant margin. The key unknowns are long-term safety data and cardiovascular outcomes, which Phase 3 trials are designed to establish.
While awaiting FDA approval, research-grade retatrutide is available from Purgo Labs with third-party COAs confirming ≥99% purity. All compounds are sold for research purposes only. Use code HEALTH for 15% off your first order.
Shop Purgo LabsUse code HEALTH for 15% off · Research use only
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.